

Kohei Shitara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/94047/publications.pdf>

Version: 2024-02-01

197
papers

15,046
citations

50276

46
h-index

22832

112
g-index

215
all docs

215
docs citations

215
times ranked

12294
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I study of the irreversible fibroblast growth factor receptor 1 α 4 inhibitor futibatinib in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2023, 114, 574-585.	3.9	13
2	Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). <i>Gastric Cancer</i> , 2022, 25, 586-597.	5.3	8
3	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2022, 23, 234-247.	10.7	268
4	Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. <i>Cancer Cell</i> , 2022, 40, 201-218.e9.	16.8	266
5	The New Era of Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 1054.	3.7	68
6	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 619-628.	5.3	18
7	Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. <i>Nature</i> , 2022, 603, 942-948.	27.8	156
8	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor α Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	1.6	9
9	Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti α PD-1 Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 2110-2117.	7.0	30
10	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel \pm Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3686-3694.	7.0	1
11	Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1413-1420.	2.2	2
12	Phase III study of pembrolizumab combined with S α oxaliplatin or S α cisplatin as first-line chemotherapy for gastric cancer. <i>Cancer Science</i> , 2022, 113, 2814-2827.	3.9	10
13	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. <i>Clinical Cancer Research</i> , 2022, 28, 3480-3488.	7.0	8
14	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab \pm Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <i>Clinical Cancer Research</i> , 2022, 28, 3489-3498.	7.0	35
15	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	1.7	2
16	Antibody α drug conjugates to treat gastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 923-930.	3.1	10
17	The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). <i>Investigational New Drugs</i> , 2021, 39, 152-162.	2.6	7
18	A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604). <i>Gastric Cancer</i> , 2021, 24, 190-196.	5.3	10

#	ARTICLE	IF	CITATIONS
19	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , 2021, 17, 491-501.	2.4	117
20	Current status of immunotherapy for advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 20-27.	1.3	43
21	Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. <i>Gastric Cancer</i> , 2021, 24, 467-476.	5.3	4
22	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10 . <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931.	7.0	53
23	Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098651.	3.2	16
24	Short-term safety of adjuvant chemoradiotherapy after local resection for patients with high-risk submucosal invasive rectal cancer: a single-arm, multicenter phase II trial. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 707-712.	1.3	2
25	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 473-487.	27.6	139
26	Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 624-636.	3.4	13
27	Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. <i>Gastric Cancer</i> , 2021, 24, 970-977.	5.3	5
28	Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 209-217.	8.1	20
29	A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3714-3724.	7.0	61
30	Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 825-830.	3.1	6
31	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 811-824.	3.1	16
32	Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy. <i>Gastric Cancer</i> , 2021, 24, 810-822.	5.3	8
33	Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1098-1107.	1.6	118
34	Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 780-789.	5.3	24
35	Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. <i>Journal of Clinical Oncology</i> , 2021, 39, 4013-4013.	1.6	75
36	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021, 7, 895.	7.1	184

#	ARTICLE	IF	CITATIONS
37	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 27-40.	13.7	1,237
38	The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e166-e173.	3.8	8
39	Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1383-1390.	1.3	9
40	Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1523-1533.	1.3	6
41	Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. <i>ESMO Open</i> , 2021, 6, 100200.	4.5	11
42	Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	7.0	27
43	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021, 24, 1330-1340.	5.3	7
44	Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1193-1201.	2.4	6
45	Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110091.	3.2	4
46	Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G. <i>Cancer Medicine</i> , 2021, 10, 7673-7682.	2.8	2
47	A Phase 2 Study of Futibatinib (TAS-120) in Patients with Myeloid or Lymphoid Neoplasms Harboring Fibroblast Growth Factor Receptor (FGFR) 1 Rearrangements. <i>Blood</i> , 2021, 138, 3656-3656.	1.4	1
48	The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. <i>Nature</i> , 2021, 600, 727-730.	27.8	335
49	Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 301-311.	2.2	8
50	Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy. <i>JAMA Oncology</i> , 2020, 6, e193531.	7.1	16
51	Trifluridine/tipiracil for the treatment of metastatic gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 65-70.	3.0	7
52	Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 5-13.	1.1	12
53	A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study). <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 89-93.	1.3	30
54	Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G). <i>Targeted Oncology</i> , 2020, 15, 623-633.	3.6	4

#	ARTICLE	IF	CITATIONS
55	Protocol for a single-arm confirmatory trial of adjuvant chemoradiation for patients with high-risk rectal submucosal invasive cancer after local resection: Japan Clinical Oncology Group Study JCOG1612 (RESCUE study). <i>BMJ Open</i> , 2020, 10, e034947.	1.9	4
56	Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab. <i>JCO Precision Oncology</i> , 2020, 4, 1407-1413.	3.0	9
57	Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094237.	3.2	7
58	Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1063-1068.	2.4	1
59	Development of circulating tumour DNA analysis for gastrointestinal cancers. <i>ESMO Open</i> , 2020, 5, e000600.	4.5	20
60	Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. <i>ESMO Open</i> , 2020, 5, e000775.	4.5	22
61	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1571.	7.1	611
62	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. <i>Nature Immunology</i> , 2020, 21, 1346-1358.	14.5	431
63	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2419-2430.	27.0	681
64	Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1057-1065.	10.7	160
65	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 893-903.	5.3	20
66	Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 855-862.	2.3	24
67	Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. <i>Gastric Cancer</i> , 2020, 23, 689-698.	5.3	16
68	An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. <i>Immunity</i> , 2020, 53, 187-203.e8.	14.3	119
69	Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). <i>Gastric Cancer</i> , 2020, 23, 677-688.	5.3	25
70	Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). <i>Journal of Clinical Oncology</i> , 2020, 38, 2053-2061.	1.6	469
71	Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 859-866.	1.3	23
72	The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3784-3790.	7.0	49

#	ARTICLE	IF	CITATIONS
73	The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4512-4512.	1.6	26
74	The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4537-4537.	1.6	38
75	A phase II study of futibatinib (TAS-120) in patients (pts) with advanced (adv) solid tumors harboring fibroblast growth factor receptor (<i>FGFR</i>) genomic aberrations.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS470-TPS470.	1.6	10
76	Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. <i>Gastric Cancer</i> , 2019, 22, 155-163.	5.3	44
77	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epsteinâ€Barr virus status, and cancer genome alterations in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 69-76.	5.3	45
78	Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples. <i>Gastric Cancer</i> , 2019, 22, 335-343.	5.3	5
79	Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia. <i>JAMA Network Open</i> , 2019, 2, e198243.	5.9	25
80	Next-generation sequencing and biomarkers for gastric cancer: what is the future?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984818.	3.2	9
81	Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 501-510.	8.1	88
82	Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study. <i>Japanese Journal of Clinical Oncology</i> , 2019, 50, 129-137.	1.3	1
83	Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for nextâ€Bgeneration sequencing. <i>Biomedical Reports</i> , 2019, 11, 171-180.	2.0	4
84	Regulatory T cells in cancer immunosuppression â€B implications for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 356-371.	27.6	872
85	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435.	10.7	191
86	First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 531-540.	4.1	49
87	A Phase I Study of Napabucasin Plus Paclitaxel for Japanese Patients With Advanced/Recurrent Gastric Cancer. <i>In Vivo</i> , 2019, 33, 933-937.	1.3	15
88	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 827-836.	10.7	154
89	PD-1 ⁺regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9999-10008.	7.1	655
90	Dawn of precision medicine on gastric cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 779-788.	2.2	15

#	ARTICLE	IF	CITATIONS
91	Phase I Study of the Focal Adhesion Kinase Inhibitor BIÂ853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. <i>Targeted Oncology</i> , 2019, 14, 57-65.	3.6	20
92	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. <i>Future Oncology</i> , 2019, 15, 943-952.	2.4	133
93	The results of Japanese subgroup analyses from TAGS: a phase 3 study of FTD/TPI (TAS-102) in heavily pretreated mGC. <i>Annals of Oncology</i> , 2019, 30, vi89.	1.2	0
94	Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 465-472.	1.5	32
95	Reply to: "Multimodal Treatment of Locally Advanced Gastric Cancer: Will the West Meet the East?" by Marino, Elisabetta et al.. <i>Annals of Surgical Oncology</i> , 2019, 26, 919-920.	1.5	0
96	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 793-802.	5.3	124
97	First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 507-518.	2.6	16
98	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4146-TPS4146.	1.6	17
99	Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA4007-LBA4007.	1.6	119
100	HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. <i>World Journal of Clinical Cases</i> , 2019, 7, 1964-1977.	0.8	39
101	Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 3964-3971.	2.4	8
102	Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 559-564.	1.3	10
103	Regulatory T cells: a potential target in cancer immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1417, 104-115.	3.8	184
104	Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer. <i>Case Reports in Oncology</i> , 2018, 11, 228-233.	0.7	0
105	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	7.1	1,350
106	Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2018, 21, 106-113.	5.3	8
107	KEYNOTE-061: pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer. <i>Annals of Oncology</i> , 2018, 29, vii49.	1.2	1
108	Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. <i>ESMO Open</i> , 2018, 3, e000443.	4.5	9

#	ARTICLE	IF	CITATIONS
109	A phase II study of nab-PTX in combination with RAM in patients with pre-treated AGC: results of final analysis. <i>Annals of Oncology</i> , 2018, 29, vii67.	1.2	0
110	Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2018, 109, 3216-3223.	3.9	12
111	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
112	Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1437-1448.	10.7	345
113	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq1 1,0784314,rgBT /O	3.9	38
114	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	13.7	984
115	The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4050-4050.	1.6	13
116	Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. <i>Gastric Cancer</i> , 2017, 20, 175-181.	5.3	77
117	Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). <i>Gastric Cancer</i> , 2017, 20, 341-349.	5.3	79
118	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. <i>Gastric Cancer</i> , 2017, 20, 904-912.	5.3	33
119	Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 277-287.	8.1	141
120	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 158-163.	2.3	13
121	Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407). <i>Gastric Cancer</i> , 2017, 20, 1004-1009.	5.3	42
122	Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e39-e44.	2.3	12
123	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncology</i> , The, 2017, 18, 640-653.	10.7	383
124	NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 569-578.	2.3	25
125	Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. <i>Lancet Oncology</i> , The, 2017, 18, 1512-1522.	10.7	317
126	TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1172-1181.	10.7	111

#	ARTICLE	IF	CITATIONS
127	Chemotherapy for advanced gastric cancer: future perspective in Japan. <i>Gastric Cancer</i> , 2017, 20, 102-110.	5.3	16
128	Clinicopathological features of programmed death ligand-1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. <i>Gastric Cancer</i> , 2017, 20, 407-415.	5.3	189
129	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. <i>British Journal of Cancer</i> , 2017, 117, 1450-1458.	6.4	52
130	Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer. <i>Oncotarget</i> , 2017, 8, 79546-79555.	1.8	21
131	Risk assessment based on the Risk Index for Serious Adverse Events (SAEs) in Phase I trials. <i>Annals of Oncology</i> , 2017, 28, ix108.	1.2	0
132	Phase I study of roniciclib (BAY1000394), an oral CDK inhibitor in Japanese patients with advanced solid tumors. <i>Annals of Oncology</i> , 2016, 27, vii87-vii88.	1.2	0
133	Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1313-1320.	4.9	19
134	Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer: WJOG 6210G. <i>Cancer Science</i> , 2016, 107, 1843-1850.	3.9	60
135	Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. <i>Clinical Colorectal Cancer</i> , 2016, 15, e109-e115.	2.3	20
136	Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1000-1007.	1.3	6
137	A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1253-1262.	2.3	4
138	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. <i>Gastric Cancer</i> , 2016, 19, 183-191.	5.3	95
139	Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 927-938.	5.3	67
140	Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case. <i>Pathology International</i> , 2015, 65, 309-317.	1.3	6
141	Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors. <i>Anti-Cancer Drugs</i> , 2015, 26, 1043-1053.	1.4	27
142	Ramucirumab for gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 133-139.	3.0	5
143	Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. <i>Investigational New Drugs</i> , 2015, 33, 664-670.	2.6	3
144	A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 1082-1086.	1.3	38

#	ARTICLE	IF	CITATIONS
145	Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 362-370.	5.3	25
146	Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1383-1389.	2.5	16
147	A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer. <i>International Journal of Clinical Oncology</i> , 2013, 18, 539-546.	2.2	11
148	Pulmonary metastasectomy for gastric cancer: a 13-year single-institution experience. <i>Surgery Today</i> , 2013, 43, 1382-1389.	1.5	20
149	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1667-1670.	6.3	78
150	Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. <i>Gastric Cancer</i> , 2013, 16, 48-55.	5.3	15
151	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1600-1607.	6.3	133
152	Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 595-603.	2.5	5
153	Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. <i>Gastric Cancer</i> , 2013, 16, 261-267.	5.3	67
154	Serum Concentration of Fentanyl During Conversion From Intravenous to Transdermal Administration to Patients With Chronic Cancer Pain. <i>Clinical Journal of Pain</i> , 2013, 29, 487-491.	1.9	19
155	Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. <i>Investigational New Drugs</i> , 2012, 30, 1224-1231.	2.6	29
156	Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. <i>Gastric Cancer</i> , 2012, 15, 137-143.	5.3	23
157	Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. <i>Gastric Cancer</i> , 2012, 15, 245-251.	5.3	19
158	Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <i>Investigational New Drugs</i> , 2012, 30, 787-793.	2.6	16
159	Trastuzumab for a patient with heavily pretreated gastric cancer plus massive ascites and ovarian metastasis. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 97-9.	0.7	0
160	Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer. <i>Japanese Journal of Cancer and Chemotherapy</i> , 2012, 39, 1511-5.	0.2	4
161	Pathological complete response of colorectal liver metastases following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab: A case report. <i>Oncology Letters</i> , 2011, 2, 201-205.	1.8	1
162	Bevacizumab Chemotherapy for Pulmonary Epithelioid Hemangioendothelioma with Severe Dyspnea. <i>Journal of Thoracic Oncology</i> , 2011, 6, 651-652.	1.1	27

#	ARTICLE	IF	CITATIONS
163	Association between insulin-like growth factor-1 polymorphisms and stomach cancer risk in a Japanese population. <i>Cancer Science</i> , 2011, 102, 2231-2235.	3.9	20
164	Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS. <i>Investigational New Drugs</i> , 2011, 29, 688-693.	2.6	12
165	Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2011, 14, 155-160.	5.3	17
166	Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2011, 16, 416-420.	2.2	6
167	A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab. <i>International Journal of Clinical Oncology</i> , 2011, 16, 766-769.	2.2	8
168	Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 301-307.	2.3	71
169	<i>ABO</i> Genotype and the Risk of Gastric Cancer, Atrophic Gastritis, and <i>Helicobacter pylori</i> Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1665-1672.	2.5	76
170	Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel vs. Standard Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 287-290.	1.3	7
171	Dramatic Tumor Response to Everolimus for Malignant Epithelioid Angiomyolipoma. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 814-816.	1.3	45
172	Lapatinib Plus Trastuzumab for a Patient with Heavily Pre-treated Gastric Cancer that Progressed after Trastuzumab. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 663-665.	1.3	7
173	Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 168-72.	0.7	13
174	FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases. <i>Japanese Journal of Cancer and Chemotherapy</i> , 2011, 38, 1205-8.	0.2	2
175	Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. <i>Anticancer Research</i> , 2011, 31, 3535-41.	1.1	44
176	Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: A retrospective study. <i>Cancer Science</i> , 2010, 101, 1001-1006.	3.9	46
177	Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 699-701.	1.3	3
178	Case Series of Cetuximab Monotherapy for Patients with Pre-treated Colorectal Cancer Complicated with Hyperbilirubinemia due to Severe Liver Metastasis. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 275-277.	1.3	6
179	Folate Intake along with Genetic Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase in Patients with Advanced Gastric Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1311-1319.	2.5	35
180	Phase I Study of Docetaxel, Cisplatin and S-1 in Patients with Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 1014-1020.	1.3	4

#	ARTICLE	IF	CITATIONS
181	A Case of Advanced Gastric Cancer with Poor Performance Status Which Improved by Chemotherapy. Case Reports in Oncology, 2010, 3, 262-267.	0.7	3
182	Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications. Case Reports in Oncology, 2010, 3, 282-286.	0.7	4
183	Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pacific Journal of Cancer Prevention, 2010, 11, 447-52.	1.2	14
184	Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. International Journal of Cancer, 2009, 125, 1961-1964.	5.1	59
185	Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. Gastrointestinal Cancer Research: GCR, 2009, 3, 66-72.	0.7	16
186	Cetuximab for patients with colon cancer and hepatic metastasis complicated by liver dysfunction and icterus. Gastrointestinal Cancer Research: GCR, 2009, 3, 171-2.	0.7	2
187	Was the unexpected result a response to reintroduction of effective chemotherapy?. Gastrointestinal Cancer Research: GCR, 2009, 3, 217-8.	0.7	0
188	Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointestinal Cancer Research: GCR, 2009, 3, 220-4.	0.7	7
189	Metastatic Rectal Cancer Responding to Third-line Therapy Employing Bevacizumab After Failure of Oxaliplatin and Irinotecan: Case Report. Japanese Journal of Clinical Oncology, 2008, 38, 493-496.	1.3	5
190	Chemotherapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1. Japanese Journal of Clinical Oncology, 2008, 38, 786-789.	1.3	13
191	A case of advanced breast cancer associated with development of liver atrophy with progressive liver failure during treatment. Japanese Journal of Cancer and Chemotherapy, 2008, 35, 983-6.	0.2	0
192	Hepatic Arterial Infusion of Oxaliplatin for a Patient with Hepatic Metastases from Colon Cancer Undergoing Hemodialysis. Japanese Journal of Clinical Oncology, 2007, 37, 540-543.	1.3	11
193	A case of suspected S-1 induced interstitial pneumonia. Japanese Journal of Cancer and Chemotherapy, 2007, 34, 619-22.	0.2	5
194	Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. Japanese Journal of Cancer and Chemotherapy, 2007, 34, 1079-84.	0.2	0
195	A case of suspected vasospastic angina related to S-1 administration. Japanese Journal of Cancer and Chemotherapy, 2007, 34, 1705-8.	0.2	1
196	Suspected paclitaxel-induced pneumonitis. Gastric Cancer, 2006, 9, 325-328.	5.3	15
197	Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy. International Journal of Clinical Oncology, 2006, 11, 367-374.	2.2	4